Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

During the Trading Day
35.91 -0.72 / -1.97%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
35.91 0.00 / 0.00%
Volume: 20.0K
Health Technology

Company Description

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is developing a portfolio consisting of four advanced product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. It also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma. ACADIA Pharmaceuticals was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Contact Information

ACADIA Pharmaceuticals, Inc.
3611 Valley Centre Drive
San Diego California 92130-3331
P:(858) 558-2871
Investor Relations:



Mutual fund holders50.57%
Other institutional48.56%
Individual stakeholders29.63%

Top Executives

Stephen R. DavisCEO, CFO, Chief Business Officer & Executive VP
Roger G. MillsChief Medical Officer & Executive VP-Development
James A. NashVice President-Technology Development & Operations
Glenn F. BaitySecretary, Executive VP & General Counsel
Ryan E. BrownChief Compliance Officer